{"parse":{"title":"Expanded access","pageid":10843800,"revid":858040299,"text":{"*":"<div class=\"mw-parser-output\"><p><b>Expanded access</b> is the use of an unapproved drug or medical device under specials forms of <a href=\"/wiki/Investigational_new_drug\" class=\"mw-redirect\" title=\"Investigational new drug\">investigational new drug applications</a> (IND) or <a href=\"/wiki/Investigational_device_exemption\" title=\"Investigational device exemption\">IDE application</a> for devices, outside of a <a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">clinical trial</a>, by people with serious or life-threatening conditions who do not meet the enrollment criteria for the clinical trial in progress.\n</p><p>These programs go under various names, including <b>early access</b>, <b>special access</b>, or <b>managed access program</b>, <b>compassionate use</b>, <b>compassionate access</b>, <b>named-patient access</b>, <b>temporary authorization for use</b>, <b>cohort access</b>, and <b>pre-approval access</b>.<sup id=\"cite_ref-Patil2016_1-0\" class=\"reference\"><a href=\"#cite_note-Patil2016-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-Balasubramanian2016_2-0\" class=\"reference\"><a href=\"#cite_note-Balasubramanian2016-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-Hyry2015_3-0\" class=\"reference\"><a href=\"#cite_note-Hyry2015-3\">&#91;3&#93;</a></sup>\n</p><p>In general the person and his or her doctor must apply for access to the investigational product, the company has to choose to cooperate, and the medicines regulatory agency needs to agree that the risks and possible benefits of the drug or device are understood well enough to determine if putting the person at risk has sufficient potential benefit.  In some countries the government will pay for the drug or device, but in many countries the person must pay for the drug or device, as well as medical services necessary to receive it.\n</p><p>In the US compassionate use started with the provision of <a href=\"/wiki/Medical_cannabis\" title=\"Medical cannabis\">medical cannabis</a> to certain people in the late 1970s, after a person with <a href=\"/wiki/Glaucoma\" title=\"Glaucoma\">glaucoma</a> sued the US government and won; that program was mostly shut down by the administration of <a href=\"/wiki/George_H.W._Bush\" class=\"mw-redirect\" title=\"George H.W. Bush\">George H.W. Bush</a>.   Another important legal case was <i><a href=\"/wiki/Abigail_Alliance_v._von_Eschenbach\" class=\"mw-redirect\" title=\"Abigail Alliance v. von Eschenbach\">Abigail Alliance v. von Eschenbach</a></i>, in which the Abigail Alliance, a group that advocates for access to investigational drugs for people who are terminally ill, tried to establish such access as a legal right, and lost.\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Programs\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Programs</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-2\"><a href=\"#US\"><span class=\"tocnumber\">1.1</span> <span class=\"toctext\">US</span></a>\n<ul>\n<li class=\"toclevel-3 tocsection-3\"><a href=\"#State_law\"><span class=\"tocnumber\">1.1.1</span> <span class=\"toctext\">State law</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#Europe\"><span class=\"tocnumber\">1.2</span> <span class=\"toctext\">Europe</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#History\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">History</span></a></li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#See_also\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#References\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Programs\">Programs</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Expanded_access&amp;action=edit&amp;section=1\" title=\"Edit section: Programs\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>As of 2016, regulation of access to pharmaceuticals that were not approved for marketing was handled on a country by country basis, including in the European Union, where the <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a> issued guidelines for national regulatory agencies to follow. In the US, Europe, and the EU, no company could be compelled to provide a drug or device that it was <a href=\"/wiki/Drug_development\" title=\"Drug development\">developing</a>.<sup id=\"cite_ref-Patil2016_1-1\" class=\"reference\"><a href=\"#cite_note-Patil2016-1\">&#91;1&#93;</a></sup>\n</p><p>Companies sometimes provide drugs under these programs to people who were in clinical trials and who responded to the drug, after the clinical trial ends.<sup id=\"cite_ref-Balasubramanian2016_2-1\" class=\"reference\"><a href=\"#cite_note-Balasubramanian2016-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-Hyry2015_3-1\" class=\"reference\"><a href=\"#cite_note-Hyry2015-3\">&#91;3&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"US\">US</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Expanded_access&amp;action=edit&amp;section=2\" title=\"Edit section: US\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In the US as of 2018, people could try obtain unapproved drugs or medical devices that were in development under specific conditions.<sup id=\"cite_ref-NCI_4-0\" class=\"reference\"><a href=\"#cite_note-NCI-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-FDAEAmain_5-0\" class=\"reference\"><a href=\"#cite_note-FDAEAmain-5\">&#91;5&#93;</a></sup>\n</p><p>These conditions were:<sup id=\"cite_ref-FDAEAmain_5-1\" class=\"reference\"><a href=\"#cite_note-FDAEAmain-5\">&#91;5&#93;</a></sup>\n</p>\n<ul><li>The person wanting the drug or device and a licensed physician are both willing to participate.</li>\n<li>The person's physician determines that there is no comparable or satisfactory therapy available to diagnose, monitor, or treat the patient\u2019s disease or condition.</li>\n<li>That the probable risk to the person from the investigational product is not greater than the probable risk from the disease or condition.</li>\n<li>The FDA determines that there is sufficient evidence of the safety and effectiveness of the investigational product to support its use in the particular circumstance;</li>\n<li>The FDA determines that providing the investigational product will not interfere with the initiation, conduct, or completion of clinical investigations to support marketing approval;</li>\n<li>The sponsor (generally the company developing the investigational product for commercial use) or the clinical investigator (or the patient\u2019s physician in the case of a single patient expanded access request) submits a clinical protocol (a document that describes the treatment plan for the patient) that is consistent with FDA\u2019s statute and applicable regulations for INDs or investigational device exemption applications (IDEs), describing the use of the investigational product; and</li>\n<li>The person is unable to obtain the investigational drug or device under another <a href=\"/wiki/Investigational_New_Drug\" title=\"Investigational New Drug\">IND application</a> (for drugs), <a href=\"/wiki/Investigational_device_exemption\" title=\"Investigational device exemption\">IDE application</a> (for devices), or to participate in a clinical trial.</li></ul>\n<p>Drugs can be made available to individuals, small groups, or large groups.<sup id=\"cite_ref-FDAEAmain_5-2\" class=\"reference\"><a href=\"#cite_note-FDAEAmain-5\">&#91;5&#93;</a></sup>\n</p><p>In the US, actual provision of the drug depends on the manufacturer's willingness to provide it, as well as the person's ability to pay for it; it is the company's decision whether to require payment or to provide the drug or device for free.<sup id=\"cite_ref-Patil2016_1-2\" class=\"reference\"><a href=\"#cite_note-Patil2016-1\">&#91;1&#93;</a></sup>  The manufacturer can only charge <a href=\"/wiki/Direct_costs\" title=\"Direct costs\">direct costs</a> for individual INDs; it can add some but not all <a href=\"/wiki/Indirect_costs\" title=\"Indirect costs\">indirect costs</a> for small group or larger expanded access programs.<sup id=\"cite_ref-Darrow2015_6-0\" class=\"reference\"><a href=\"#cite_note-Darrow2015-6\">&#91;6&#93;</a></sup> To the extent that a doctor or clinic is required for use of the drug or device, they too may require payment.<sup id=\"cite_ref-Patil2016_1-3\" class=\"reference\"><a href=\"#cite_note-Patil2016-1\">&#91;1&#93;</a></sup>\n</p><p>In some cases, it may be in the manufacturer's commercial interest to provide access under an EA program; this is a way, for example, for a company to make money before the drug or device is approved.  Companies must provide data collected from people getting the drug or device under EA programs to the FDA annually; this data may be helpful with regard to getting the drug or device approved, or may be harmful, should unexpected adverse events occur.  The manufacturer remains legally liable as well. If the manufacturer chooses to charge for the investigational product, that price influences later discussions about the price if the product is approved for marketing.<sup id=\"cite_ref-Patil2016_1-4\" class=\"reference\"><a href=\"#cite_note-Patil2016-1\">&#91;1&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"State_law\">State law</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Expanded_access&amp;action=edit&amp;section=3\" title=\"Edit section: State law\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>As of September 2016, 32 states have passed <a href=\"/wiki/Right-to-try_laws\" class=\"mw-redirect\" title=\"Right-to-try laws\">right-to-try laws</a> that permit manufacturers to provide experimental medicines to terminally ill people without US FDA authorization.<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup>  Legal, medical, and bioethics scholars, including Jonathan Darrow and Arthur Caplan, have argued that these state laws have little practical significance because people can already obtain pre-approval access through the FDA's expanded access program, and because the FDA is generally not the limiting factor in obtaining pre-approval access.<sup id=\"cite_ref-:0_8-0\" class=\"reference\"><a href=\"#cite_note-:0-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Europe\">Europe</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Expanded_access&amp;action=edit&amp;section=4\" title=\"Edit section: Europe\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In Europe, the <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a> issued guidelines that members may follow.  Each country has its own regulations, and they vary.  In the UK, for example, the program is called \"early access to medicine scheme\" or EAMS and was established in 2014. If a company that wants to provide a drug under EAMS, it must submit its Phase I data to the <a href=\"/wiki/Medicines_and_Healthcare_products_Regulatory_Agency\" title=\"Medicines and Healthcare products Regulatory Agency\">Medicines and Healthcare products Regulatory Agency</a> and apply for what is called a \"promising innovative medicine\" (PIM) designation.  If that designation is approved, the data is reviewed, if that review is positive, the <a href=\"/wiki/National_Health_Service\" title=\"National Health Service\">National Health Service</a> is obligated to pay for people who fit the criteria to have access to the drug. As of 2016, governments also paid for early access to drugs in Austria, Germany, Greece, and Spain.<sup id=\"cite_ref-Patil2016_1-5\" class=\"reference\"><a href=\"#cite_note-Patil2016-1\">&#91;1&#93;</a></sup>\n</p><p>Companies sometimes make use of expanded programs in Europe even after they receive EMA approval to market a drug, because drugs also much go through regulatory processes in each member state, and in some countries this process can take nearly a year; companies can start making sales earlier under these programs.<sup id=\"cite_ref-Patil2016_1-6\" class=\"reference\"><a href=\"#cite_note-Patil2016-1\">&#91;1&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"History\">History</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Expanded_access&amp;action=edit&amp;section=5\" title=\"Edit section: History\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:222px;\"><a href=\"/wiki/File:U.S._Government_Medical_Marijuana_crop._University_of_Mississippi._Oxford.jpg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/3/3f/U.S._Government_Medical_Marijuana_crop._University_of_Mississippi._Oxford.jpg/220px-U.S._Government_Medical_Marijuana_crop._University_of_Mississippi._Oxford.jpg\" width=\"220\" height=\"165\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/3/3f/U.S._Government_Medical_Marijuana_crop._University_of_Mississippi._Oxford.jpg/330px-U.S._Government_Medical_Marijuana_crop._University_of_Mississippi._Oxford.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/3/3f/U.S._Government_Medical_Marijuana_crop._University_of_Mississippi._Oxford.jpg/440px-U.S._Government_Medical_Marijuana_crop._University_of_Mississippi._Oxford.jpg 2x\" data-file-width=\"1280\" data-file-height=\"960\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:U.S._Government_Medical_Marijuana_crop._University_of_Mississippi._Oxford.jpg\" class=\"internal\" title=\"Enlarge\"></a></div>Medicinal cannabis farmed by the <a href=\"/wiki/University_of_Mississippi\" title=\"University of Mississippi\">University of Mississippi</a> for the government</div></div></div>\n<p>In the US, one of the earliest expanded access programs was a compassionate use IND that was established in 1978, which allowed a limited number of people to use <a href=\"/wiki/Medical_cannabis\" title=\"Medical cannabis\">medical cannabis</a> grown at the <a href=\"/wiki/University_of_Mississippi\" title=\"University of Mississippi\">University of Mississippi</a>.  It is administered by the <a href=\"/wiki/National_Institute_on_Drug_Abuse\" title=\"National Institute on Drug Abuse\">National Institute on Drug Abuse</a>.\n</p><p>The program was started after <a href=\"/wiki/Robert_C._Randall\" title=\"Robert C. Randall\">Robert C. Randall</a>  brought a lawsuit (<i>Randall v. U.S</i>)<sup id=\"cite_ref-BenAmar2006_10-0\" class=\"reference\"><a href=\"#cite_note-BenAmar2006-10\">&#91;10&#93;</a></sup> against the FDA, the <a href=\"/wiki/Drug_Enforcement_Administration\" title=\"Drug Enforcement Administration\">Drug Enforcement Administration</a>, the <a href=\"/wiki/National_Institute_on_Drug_Abuse\" title=\"National Institute on Drug Abuse\">National Institute on Drug Abuse</a>, the <a href=\"/wiki/United_States_Department_of_Justice\" title=\"United States Department of Justice\">Department of Justice</a>, and the <a href=\"/wiki/United_States_Department_of_Health_and_Human_Services\" title=\"United States Department of Health and Human Services\">Department of Health, Education &amp; Welfare</a>.  Randall, who had <a href=\"/wiki/Glaucoma\" title=\"Glaucoma\">glaucoma</a>, had successfully used the <i>Common Law doctrine of necessity</i> to argue against criminal charges of marijuana cultivation that had been brought against him, because his use of cannabis was deemed a <a href=\"/wiki/Medical_necessity\" title=\"Medical necessity\">medical necessity</a> (<i>U.S. v. Randall</i>).<sup id=\"cite_ref-BenAmar2006_10-1\" class=\"reference\"><a href=\"#cite_note-BenAmar2006-10\">&#91;10&#93;</a></sup> On November 24, 1976, federal Judge James Washington ruled in his favor.<sup id=\"cite_ref-Lee_11-0\" class=\"reference\"><a href=\"#cite_note-Lee-11\">&#91;11&#93;</a></sup><sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup>\n</p><p>The settlement in <i>Randall v. U.S.</i> became the legal basis for the FDA's compassionate IND program.<sup id=\"cite_ref-BenAmar2006_10-2\" class=\"reference\"><a href=\"#cite_note-BenAmar2006-10\">&#91;10&#93;</a></sup>  People were only allowed to use cannabis under the program who had certain conditions, like glaucoma, known to be alleviated with cannabis.  The scope was laster expanded to include people with <a href=\"/wiki/AIDS\" class=\"mw-redirect\" title=\"AIDS\">AIDS</a> in the mid-1980s. At its peak, fifteen people received the drug. 43 people were approved for the program, but 28 of the people whose doctors completed the necessary paperwork never received any cannabis.<sup id=\"cite_ref-LeaderTelegram_13-0\" class=\"reference\"><a href=\"#cite_note-LeaderTelegram-13\">&#91;13&#93;</a></sup><sup id=\"cite_ref-Smoke_Signals_14-0\" class=\"reference\"><a href=\"#cite_note-Smoke_Signals-14\">&#91;14&#93;</a></sup> The program stopped accepting new people in 1992 after public health authorities concluded there was no scientific value to it, and due to President <a href=\"/wiki/George_H.W._Bush\" class=\"mw-redirect\" title=\"George H.W. Bush\">George H.W. Bush</a> administration's policies.  As of 2011, four people continued to receive cannabis from the government under the program.<sup id=\"cite_ref-4_Americans_get_medical_pot_from_the_feds_15-0\" class=\"reference\"><a href=\"#cite_note-4_Americans_get_medical_pot_from_the_feds-15\">&#91;15&#93;</a></sup>\n</p><p>The closure of the program during the height of the AIDS epidemic led to the formation of the medical cannabis movement in the United States, a movement which initially sought to provide cannabis for treating anorexia and wasting syndrome in people with AIDS.<sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup>\n</p><p>In November 2001 the Abigail Alliance for Better Access to Developmental Drugs was established by Frank Burroughs in memory of his daughter, Abigail.<sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup>   The Alliance seeks broader availability of investigational drugs on behalf of people with terminal illnesses.  It is best known for a legal case, which it lost, <i><a href=\"/wiki/Abigail_Alliance_v._von_Eschenbach\" class=\"mw-redirect\" title=\"Abigail Alliance v. von Eschenbach\">Abigail Alliance v. von Eschenbach</a></i>, in which it was represented by the <a href=\"/wiki/Washington_Legal_Foundation\" title=\"Washington Legal Foundation\">Washington Legal Foundation</a>. On August 7, 2007, in an 8\u20132 ruling, the <a href=\"/wiki/U.S._Court_of_Appeals_for_the_District_of_Columbia_Circuit\" class=\"mw-redirect\" title=\"U.S. Court of Appeals for the District of Columbia Circuit\">U.S. Court of Appeals for the District of Columbia Circuit</a> reversed an earlier ruling in favor of the Alliance.<sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup>  In 2008, the <a href=\"/wiki/Supreme_Court_of_the_United_States\" title=\"Supreme Court of the United States\">Supreme Court of the United States</a> declined to hear their appeal. This decision left standing the appellate court decision that people who are terminal ill patients have no legal right to demand \"a potentially toxic drug with no proven therapeutic benefit\".<sup id=\"cite_ref-afp2008_19-0\" class=\"reference\"><a href=\"#cite_note-afp2008-19\">&#91;19&#93;</a></sup>\n</p><p>In March 2014, Josh Hardy, a 7-year-old boy from Virginia, made national headlines that sparked a conversation on pediatric access to investigational drugs when his family's request for brincidofovir was declined by the drug manufacturer, Chimerix.<sup id=\"cite_ref-20\" class=\"reference\"><a href=\"#cite_note-20\">&#91;20&#93;</a></sup> The company reversed its decision after pressure from cancer advocacy organizations, and Josh received the drug that saved his life.<sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup> In 2016 Kids v Cancer, a pediatric cancer advocacy organization, launched the Compassionate Use Navigator to assist physicians and guide families about the application process.<sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup> Since then, FDA simplified the application process, but stressed that it cannot require a manufacturer to provide a product.<sup id=\"cite_ref-24\" class=\"reference\"><a href=\"#cite_note-24\">&#91;24&#93;</a></sup> <sup id=\"cite_ref-25\" class=\"reference\"><a href=\"#cite_note-25\">&#91;25&#93;</a></sup> FDA receives about 1,500 expanded access requests per year and authorizes 99% of it.<sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup>  \n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Expanded_access&amp;action=edit&amp;section=6\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Orphan_drug\" title=\"Orphan drug\">Orphan drug</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Expanded_access&amp;action=edit&amp;section=7\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png\" width=\"12\" height=\"12\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x\" data-file-width=\"196\" data-file-height=\"196\" />&#160;This article incorporates&#160;<a href=\"/wiki/Copyright_status_of_work_by_the_U.S._government\" title=\"Copyright status of work by the U.S. government\">public domain material</a> from the <a href=\"/wiki/United_States_Department_of_Health_and_Human_Services\" title=\"United States Department of Health and Human Services\">United States Department of Health and Human Services</a>&#32;document <a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/default.htm\">\"Expanded Access (Compassionate Use)\"</a>.<span class=\"reference-accessdate\">&#32;Retrieved on 2018-05-20.</span>\n</p>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-Patil2016-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Patil2016_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Patil2016_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Patil2016_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Patil2016_1-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Patil2016_1-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Patil2016_1-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Patil2016_1-6\"><sup><i><b>g</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Patil, S (2016). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4763516\">\"Early access programs: Benefits, challenges, and key considerations for successful implementation\"</a>. <i>Perspectives in clinical research</i>. <b>7</b> (1): 4\u20138. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.4103/2229-3485.173779\">10.4103/2229-3485.173779</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4763516\">4763516</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26955570\">26955570</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Perspectives+in+clinical+research&amp;rft.atitle=Early+access+programs%3A+Benefits%2C+challenges%2C+and+key+considerations+for+successful+implementation.&amp;rft.volume=7&amp;rft.issue=1&amp;rft.pages=4-8&amp;rft.date=2016&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4763516&amp;rft_id=info%3Apmid%2F26955570&amp;rft_id=info%3Adoi%2F10.4103%2F2229-3485.173779&amp;rft.aulast=Patil&amp;rft.aufirst=S&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4763516&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Balasubramanian2016-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Balasubramanian2016_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Balasubramanian2016_2-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation\">Balasubramanian, G.; Morampudi, S.; Chhabra, P.; Gowda, A.; Zomorodi, B. (2016), \"An overview of Compassionate Use Programs in the European Union member states\", <i>Intractable &amp; Rare Diseases Research</i>, <b>5</b> (4): 244\u2013254, <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.5582/irdr.2016.01054\">10.5582/irdr.2016.01054</a>, <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5116859\">5116859</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Intractable+%26+Rare+Diseases+Research&amp;rft.atitle=An+overview+of+Compassionate+Use+Programs+in+the+European+Union+member+states&amp;rft.volume=5&amp;rft.issue=4&amp;rft.pages=244-254&amp;rft.date=2016&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5116859&amp;rft_id=info%3Adoi%2F10.5582%2Firdr.2016.01054&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Uses authors parameter (<a href=\"/wiki/Category:CS1_maint:_Uses_authors_parameter\" title=\"Category:CS1 maint: Uses authors parameter\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-Hyry2015-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Hyry2015_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Hyry2015_3-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Hyry, HI; Manuel, J; Cox, TM; Roos, JC (21 August 2015). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4546220\">\"Compassionate use of orphan drugs\"</a>. <i>Orphanet journal of rare diseases</i>. <b>10</b>: 100. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1186/s13023-015-0306-x\">10.1186/s13023-015-0306-x</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4546220\">4546220</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26292942\">26292942</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Orphanet+journal+of+rare+diseases&amp;rft.atitle=Compassionate+use+of+orphan+drugs.&amp;rft.volume=10&amp;rft.pages=100&amp;rft.date=2015-08-21&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4546220&amp;rft_id=info%3Apmid%2F26292942&amp;rft_id=info%3Adoi%2F10.1186%2Fs13023-015-0306-x&amp;rft.aulast=Hyry&amp;rft.aufirst=HI&amp;rft.au=Manuel%2C+J&amp;rft.au=Cox%2C+TM&amp;rft.au=Roos%2C+JC&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4546220&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-NCI-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-NCI_4-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancer.gov/cancertopics/factsheet/Therapy/investigational-drug-access\">\"US National Cancer Institute - Access to Investigational Drugs\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=US+National+Cancer+Institute+-+Access+to+Investigational+Drugs&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Ffactsheet%2FTherapy%2Finvestigational-drug-access&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-FDAEAmain-5\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-FDAEAmain_5-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-FDAEAmain_5-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-FDAEAmain_5-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/default.htm\">\"Expanded Access (Compassionate Use)\"</a>. FDA. 27 April 2018<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">21 May</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Expanded+Access+%28Compassionate+Use%29&amp;rft.pub=FDA&amp;rft.date=2018-04-27&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FPublicHealthFocus%2FExpandedAccessCompassionateUse%2Fdefault.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Darrow2015-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Darrow2015_6-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Darrow, JJ; Sarpatwari, A; Avorn, J; Kesselheim, AS (15 January 2015). \"Practical, legal, and ethical issues in expanded access to investigational drugs\". <i>The New England Journal of Medicine</i>. <b>372</b> (3): 279\u201386. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJMhle1409465\">10.1056/NEJMhle1409465</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25587952\">25587952</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+England+Journal+of+Medicine&amp;rft.atitle=Practical%2C+legal%2C+and+ethical+issues+in+expanded+access+to+investigational+drugs.&amp;rft.volume=372&amp;rft.issue=3&amp;rft.pages=279-86&amp;rft.date=2015-01-15&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMhle1409465&amp;rft_id=info%3Apmid%2F25587952&amp;rft.aulast=Darrow&amp;rft.aufirst=JJ&amp;rft.au=Sarpatwari%2C+A&amp;rft.au=Avorn%2C+J&amp;rft.au=Kesselheim%2C+AS&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Darrow JJ;  et al. (Jan 2015). \"Practical, legal, and ethical issues in expanded access to investigational drugs\". <i>N Engl J Med</i>. <b>372</b> (3): 279\u201386. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJMhle1409465\">10.1056/NEJMhle1409465</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25587952\">25587952</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N+Engl+J+Med&amp;rft.atitle=Practical%2C+legal%2C+and+ethical+issues+in+expanded+access+to+investigational+drugs&amp;rft.volume=372&amp;rft.issue=3&amp;rft.pages=279-86&amp;rft.date=2015-01&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMhle1409465&amp;rft_id=info%3Apmid%2F25587952&amp;rft.au=Darrow+JJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:0-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-:0_8-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Darrow, Jonathan J.; Sarpatwari, Ameet; Avorn, Jerry; Kesselheim, Aaron S. (2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://dx.doi.org/10.1056/NEJMhle1409465\">\"Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs\"</a>. <i>New England Journal of Medicine</i>. <b>372</b> (3): 279\u2013286. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJMhle1409465\">10.1056/NEJMhle1409465</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0028-4793\">0028-4793</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25587952\">25587952</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+England+Journal+of+Medicine&amp;rft.atitle=Practical%2C+Legal%2C+and+Ethical+Issues+in+Expanded+Access+to+Investigational+Drugs&amp;rft.volume=372&amp;rft.issue=3&amp;rft.pages=279-286&amp;rft.date=2015&amp;rft.issn=0028-4793&amp;rft_id=info%3Apmid%2F25587952&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMhle1409465&amp;rft.aulast=Darrow&amp;rft.aufirst=Jonathan+J.&amp;rft.au=Sarpatwari%2C+Ameet&amp;rft.au=Avorn%2C+Jerry&amp;rft.au=Kesselheim%2C+Aaron+S.&amp;rft_id=https%3A%2F%2Fdx.doi.org%2F10.1056%2FNEJMhle1409465&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Caplan, A. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.cancernetwork.com/oncology-journal/medical-ethicist-arthur-caplan-explains-why-he-opposes-right-try-laws\">\"Medical Ethicist Arthur Caplan Explains Why He Opposes 'Right-to-Try' Laws\"</a>. <i>CancerNetwork.com</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=CancerNetwork.com&amp;rft.atitle=Medical+Ethicist+Arthur+Caplan+Explains+Why+He+Opposes+%E2%80%98Right-to-Try%E2%80%99+Laws&amp;rft.aulast=Caplan&amp;rft.aufirst=A&amp;rft_id=http%3A%2F%2Fwww.cancernetwork.com%2Foncology-journal%2Fmedical-ethicist-arthur-caplan-explains-why-he-opposes-right-try-laws&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-BenAmar2006-10\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-BenAmar2006_10-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-BenAmar2006_10-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-BenAmar2006_10-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Ben Amar M (2006). \"Cannabinoids in medicine: a review of their therapeutic potential\". <i>Journal of Ethnopharmacology</i>. <b>105</b> (1\u20132): 1\u201325. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.jep.2006.02.001\">10.1016/j.jep.2006.02.001</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/16540272\">16540272</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Ethnopharmacology&amp;rft.atitle=Cannabinoids+in+medicine%3A+a+review+of+their+therapeutic+potential&amp;rft.volume=105&amp;rft.issue=1%E2%80%932&amp;rft.pages=1-25&amp;rft.date=2006&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jep.2006.02.001&amp;rft_id=info%3Apmid%2F16540272&amp;rft.au=Ben+Amar+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Lee-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Lee_11-0\">^</a></b></span> <span class=\"reference-text\">Lee, M. A. (2012). <i>Smoke Signals: A Social History of Marijuana - Medical, Recreational and Scientific</i>. Simon and Schuster. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/143912793X\" title=\"Special:BookSources/143912793X\">143912793X</a>.</span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\">The Criminal Law Reporter. 20. Bureau of National Affairs. Arlington, Va.  1976. p. 2300.</span>\n</li>\n<li id=\"cite_note-LeaderTelegram-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-LeaderTelegram_13-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Rupnow, Chuck (August 9, 1997). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.mapinc.org/drugnews/v97/n318/a03.html\">\"Painful journey: Woman aims to gain support for marijuana as medicine\"</a>. <i><a href=\"/wiki/Eau_Claire_Leader-Telegram\" title=\"Eau Claire Leader-Telegram\">Eau Claire Leader-Telegram</a></i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Eau+Claire+Leader-Telegram&amp;rft.atitle=Painful+journey%3A+Woman+aims+to+gain+support+for+marijuana+as+medicine&amp;rft.date=1997-08-09&amp;rft.au=Rupnow%2C+Chuck&amp;rft_id=http%3A%2F%2Fwww.mapinc.org%2Fdrugnews%2Fv97%2Fn318%2Fa03.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Smoke_Signals-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Smoke_Signals_14-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Lee, Martin A. (August 2012). <a rel=\"nofollow\" class=\"external text\" href=\"https://books.google.com/books?id=n-SG3oWUjhMC&amp;pg=PA234&amp;lpg=PA234&amp;dq=jacki+rickert&amp;source=bl&amp;ots=G49pTLqJnI&amp;sig=9kzur-bBPe7kFWCK0ocPAQx0TmI&amp;hl=en&amp;sa=X&amp;ved=0ahUKEwiSutbg453SAhVB5IMKHT1kDMY4HhDoAQgcMAE#v=onepage&amp;q=jacki%20rickert&amp;f=false\">\"Smoke Signals: A Social History of Marijuana - Medical, Recreational and Scientific, p. 234\"</a>. <i><a href=\"/wiki/Simon_%26_Schuster\" title=\"Simon &amp; Schuster\">Simon &amp; Schuster</a></i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Simon+%26+Schuster&amp;rft.atitle=Smoke+Signals%3A+A+Social+History+of+Marijuana+-+Medical%2C+Recreational+and+Scientific%2C+p.+234&amp;rft.date=2012-08&amp;rft.au=Lee%2C+Martin+A.&amp;rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3Dn-SG3oWUjhMC%26pg%3DPA234%26lpg%3DPA234%26dq%3Djacki%2Brickert%26source%3Dbl%26ots%3DG49pTLqJnI%26sig%3D9kzur-bBPe7kFWCK0ocPAQx0TmI%26hl%3Den%26sa%3DX%26ved%3D0ahUKEwiSutbg453SAhVB5IMKHT1kDMY4HhDoAQgcMAE%23v%3Donepage%26q%3Djacki%2520rickert%26f%3Dfalse&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-4_Americans_get_medical_pot_from_the_feds-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4_Americans_get_medical_pot_from_the_feds_15-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">AP (September 27, 2011). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.cbsnews.com/news/4-americans-get-medical-pot-from-the-feds/\">\"4 Americans get medical pot from the feds\"</a>. <i>Associated Press News</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Associated+Press+News&amp;rft.atitle=4+Americans+get+medical+pot+from+the+feds&amp;rft.date=2011-09-27&amp;rft.au=AP&amp;rft_id=http%3A%2F%2Fwww.cbsnews.com%2Fnews%2F4-americans-get-medical-pot-from-the-feds%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Werner, Clinton A. (June 2001). \"Medical Marijuana and the AIDS Crisis\". <i>Journal of Cannabis Therapeutics</i>. <b>1</b> (3-4): 17\u201333. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1300/J175v01n03_03\">10.1300/J175v01n03_03</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Cannabis+Therapeutics&amp;rft.atitle=Medical+Marijuana+and+the+AIDS+Crisis&amp;rft.volume=1&amp;rft.issue=3-4&amp;rft.pages=17-33&amp;rft.date=2001-06&amp;rft_id=info%3Adoi%2F10.1300%2FJ175v01n03_03&amp;rft.aulast=Werner&amp;rft.aufirst=Clinton+A.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Phillips, Lisa (4 September 2008). \"Contract Law and Ethical Issues Underscore the Latest Lawsuit About Access to Experimental Drugs for Duchenne Muscular Dystrophy\". <i><a href=\"/w/index.php?title=Neurology_Today&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Neurology Today (page does not exist)\">Neurology Today</a></i> <span style=\"font-size:85%;\">(PDF)</span><span style=\"display:none;font-size:100%\" class=\"error citation-comment\"><code style=\"color:inherit; border:inherit; padding:inherit;\">&#124;format=</code> requires <code style=\"color:inherit; border:inherit; padding:inherit;\">&#124;url=</code> (<a href=\"/wiki/Help:CS1_errors#format_missing_url\" title=\"Help:CS1 errors\">help</a>)</span>. <b>8</b> (17): 20. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1097/01.nt.0000337676.20893.50\">10.1097/01.nt.0000337676.20893.50</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neurology+Today&amp;rft.atitle=Contract+Law+and+Ethical+Issues+Underscore+the+Latest+Lawsuit+About+Access+to+Experimental+Drugs+for+Duchenne+Muscular+Dystrophy&amp;rft.volume=8&amp;rft.issue=17&amp;rft.pages=20&amp;rft.date=2008-09-04&amp;rft_id=info%3Adoi%2F10.1097%2F01.nt.0000337676.20893.50&amp;rft.aulast=Phillips&amp;rft.aufirst=Lisa&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span> <span style=\"position:relative; top: -2px;\"><a href=\"/wiki/Open_access\" title=\"open access publication \u2013 free to read\"><img alt=\"open access publication \u2013 free to read\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/7/77/Open_Access_logo_PLoS_transparent.svg/9px-Open_Access_logo_PLoS_transparent.svg.png\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/7/77/Open_Access_logo_PLoS_transparent.svg/14px-Open_Access_logo_PLoS_transparent.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/7/77/Open_Access_logo_PLoS_transparent.svg/18px-Open_Access_logo_PLoS_transparent.svg.png 2x\" data-file-width=\"640\" data-file-height=\"1000\" /></a></span></span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ncahf.org/digest07/07-30.html\">\"Your Weekly Update of News and Reviews\"</a>. <i>Consumer Health Digest</i>. National Council Against Health Fraud (#07-30). 7 August 2007.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Consumer+Health+Digest&amp;rft.atitle=Your+Weekly+Update+of+News+and+Reviews&amp;rft.issue=%2307-30&amp;rft.date=2007-08-07&amp;rft_id=http%3A%2F%2Fwww.ncahf.org%2Fdigest07%2F07-30.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-afp2008-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-afp2008_19-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20120305014138/http://afp.google.com/article/ALeqM5jgwM6ty2aFly_TqIoojwZCheBCsw\">\"No right to experimental drugs for dying patients: Supreme Court\"</a>. <a href=\"/wiki/Google_News\" title=\"Google News\">Google News</a>. <a href=\"/wiki/Agence_France-Presse\" title=\"Agence France-Presse\">Agence France-Presse</a>. 14 January 2008. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://afp.google.com/article/ALeqM5jgwM6ty2aFly_TqIoojwZCheBCsw\">the original</a> on 5 March 2012<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">7 July</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=No+right+to+experimental+drugs+for+dying+patients%3A+Supreme+Court&amp;rft.pub=Google+News&amp;rft.date=2008-01-14&amp;rft_id=http%3A%2F%2Fafp.google.com%2Farticle%2FALeqM5jgwM6ty2aFly_TqIoojwZCheBCsw&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-20\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Correspondent, By Elizabeth Cohen, Senior Medical. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.cnn.com/2014/03/10/health/cohen-josh/index.html\">\"Company denies drug to dying child - CNN\"</a>. <i>CNN</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-07-06</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CNN&amp;rft.atitle=Company+denies+drug+to+dying+child+-+CNN&amp;rft.aulast=Correspondent&amp;rft.aufirst=By+Elizabeth+Cohen%2C+Senior+Medical&amp;rft_id=https%3A%2F%2Fwww.cnn.com%2F2014%2F03%2F10%2Fhealth%2Fcohen-josh%2Findex.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.kidsvcancer.org/saved-josh-the-gears-of-a-successful-patient-advocacy-campaign-case-study-by-elena-gerasimov/\">\"Saved Josh: The gears of  a successful  patient advocacy  campaign (Case study, by Elena Gerasimov) | Kids v Cancer\"</a>. <i>www.kidsvcancer.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-07-06</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.kidsvcancer.org&amp;rft.atitle=Saved+Josh%3A+The+gears+of++a+successful++patient+advocacy++campaign+%28Case+study%2C+by+Elena+Gerasimov%29+%7C+Kids+v+Cancer&amp;rft_id=https%3A%2F%2Fwww.kidsvcancer.org%2Fsaved-josh-the-gears-of-a-successful-patient-advocacy-campaign-case-study-by-elena-gerasimov%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">CNN, By Catherine E. Shoichet and Elizabeth Cohen,. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.cnn.com/2014/03/11/health/josh-hardy-drug-study/index.html\">\"Drug company: Ailing 7-year-old Josh Hardy will get medicine  - CNN\"</a>. <i>CNN</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-07-06</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CNN&amp;rft.atitle=Drug+company%3A+Ailing+7-year-old+Josh+Hardy+will+get+medicine++-+CNN&amp;rft.aulast=CNN&amp;rft.aufirst=By+Catherine+E.+Shoichet+and+Elizabeth+Cohen%2C&amp;rft_id=https%3A%2F%2Fwww.cnn.com%2F2014%2F03%2F11%2Fhealth%2Fjosh-hardy-drug-study%2Findex.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Gerasimov, Elena; Zhang, Lindy; Moerdler, Scott; Roth, Michael; Goodman, Nancy; Weiser, Daniel (2016-07-15). <a rel=\"nofollow\" class=\"external text\" href=\"http://cancerres.aacrjournals.org/content/76/14_Supplement/LB-146\">\"Abstract LB-146: Compassionate use navigator addresses challenges and facilitates access to investigational drugs for pediatric oncologists\"</a>. <i>Cancer Research</i>. <b>76</b> (14 Supplement): LB\u2013146\u2013LB\u2013146. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1158/1538-7445.AM2016-LB-146\">10.1158/1538-7445.AM2016-LB-146</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0008-5472\">0008-5472</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Research&amp;rft.atitle=Abstract+LB-146%3A+Compassionate+use+navigator+addresses+challenges+and+facilitates+access+to+investigational+drugs+for+pediatric+oncologists&amp;rft.volume=76&amp;rft.issue=14+Supplement&amp;rft.pages=LB-146-LB-146&amp;rft.date=2016-07-15&amp;rft_id=info%3Adoi%2F10.1158%2F1538-7445.AM2016-LB-146&amp;rft.issn=0008-5472&amp;rft.aulast=Gerasimov&amp;rft.aufirst=Elena&amp;rft.au=Zhang%2C+Lindy&amp;rft.au=Moerdler%2C+Scott&amp;rft.au=Roth%2C+Michael&amp;rft.au=Goodman%2C+Nancy&amp;rft.au=Weiser%2C+Daniel&amp;rft_id=http%3A%2F%2Fcancerres.aacrjournals.org%2Fcontent%2F76%2F14_Supplement%2FLB-146&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-24\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://blogs.fda.gov/fdavoice/index.php/2017/10/expanded-access-fda-describes-efforts-to-ease-application-process/\">\"Expanded Access: FDA Describes Efforts to Ease Application Process | FDA Voice\"</a>. <i>blogs.fda.gov</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-07-06</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=blogs.fda.gov&amp;rft.atitle=Expanded+Access%3A+FDA+Describes+Efforts+to+Ease+Application+Process+%7C+FDA+Voice&amp;rft_id=https%3A%2F%2Fblogs.fda.gov%2Ffdavoice%2Findex.php%2F2017%2F10%2Fexpanded-access-fda-describes-efforts-to-ease-application-process%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-25\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.medscape.com/viewarticle/864310\">\"Medscape Log In\"</a>. <i>www.medscape.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-07-06</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.medscape.com&amp;rft.atitle=Medscape+Log+In&amp;rft_id=https%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F864310&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Commissioner, Office of the. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/newsevents/publichealthfocus/expandedaccesscompassionateuse/ucm443572.htm\">\"Expanded Access (Compassionate Use) - Expanded Access INDs and Protocols 2009 - 2017\"</a>. <i>www.fda.gov</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-07-06</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fda.gov&amp;rft.atitle=Expanded+Access+%28Compassionate+Use%29+-+Expanded+Access+INDs+and+Protocols+2009+-+2017&amp;rft.aulast=Commissioner&amp;rft.aufirst=Office+of+the&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2Fnewsevents%2Fpublichealthfocus%2Fexpandedaccesscompassionateuse%2Fucm443572.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AExpanded+access\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n\n<!-- \nNewPP limit report\nParsed by mw1244\nCached time: 20180904175842\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.312 seconds\nReal time usage: 0.361 seconds\nPreprocessor visited node count: 1437/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 49607/2097152 bytes\nTemplate argument size: 1284/2097152 bytes\nHighest expansion depth: 16/40\nExpensive parser function count: 1/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 35476/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.133/10.000 seconds\nLua memory usage: 3.06 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  277.811      1 -total\n 97.77%  271.629      1 Template:Reflist\n 39.46%  109.613     10 Template:Cite_journal\n 16.67%   46.320     10 Template:Cite_web\n 11.59%   32.204      1 Template:ISBN\n  4.99%   13.876      3 Template:Cite_news\n  4.66%   12.955      1 Template:Catalog_lookup_link\n  3.33%    9.258      1 Template:Citation\n  2.87%    7.974      1 Template:Error-small\n  2.20%    6.114      1 Template:HHS_content\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:10843800-0!canonical and timestamp 20180904175842 and revision id 858040299\n -->\n</div>"},"langlinks":[{"lang":"de","url":"https://de.wikipedia.org/wiki/Compassionate_Use","langname":"German","autonym":"Deutsch","*":"Compassionate Use"},{"lang":"fr","url":"https://fr.wikipedia.org/wiki/Autorisation_temporaire_d%27utilisation","langname":"French","autonym":"fran\u00e7ais","*":"Autorisation temporaire d'utilisation"},{"lang":"ko","url":"https://ko.wikipedia.org/wiki/%EB%8F%99%EC%A0%95%EC%A0%81%EC%82%AC%EC%9A%A9%EC%8A%B9%EC%9D%B8%EA%B3%84%ED%9A%8D","langname":"Korean","autonym":"\ud55c\uad6d\uc5b4","*":"\ub3d9\uc815\uc801\uc0ac\uc6a9\uc2b9\uc778\uacc4\ud68d"},{"lang":"it","url":"https://it.wikipedia.org/wiki/Cura_compassionevole","langname":"Italian","autonym":"italiano","*":"Cura compassionevole"},{"lang":"ro","url":"https://ro.wikipedia.org/wiki/Uz_compasional","langname":"Romanian","autonym":"rom\u00e2n\u0103","*":"Uz compasional"},{"lang":"sl","url":"https://sl.wikipedia.org/wiki/So%C4%8Dutna_uporaba_zdravil","langname":"Slovenian","autonym":"sloven\u0161\u010dina","*":"So\u010dutna uporaba zdravil"}],"categories":[{"sortkey":"","hidden":"","*":"CS1_maint:_Uses_authors_parameter"},{"sortkey":"","hidden":"","*":"Pages_using_citations_with_format_and_no_URL"},{"sortkey":"Expanded Access","hidden":"","*":"Wikipedia_articles_incorporating_text_from_the_United_States_Department_of_Health_and_Human_Services"},{"sortkey":"Expanded Access","*":"Clinical_pharmacology"},{"sortkey":"Expanded Access","*":"Clinical_research"}],"links":[{"ns":0,"exists":"","*":"United States Department of Health and Human Services"},{"ns":0,"exists":"","*":"Open access"},{"ns":0,"exists":"","*":"AIDS"},{"ns":0,"exists":"","*":"Abigail Alliance v. von Eschenbach"},{"ns":0,"exists":"","*":"Agence France-Presse"},{"ns":0,"exists":"","*":"Clinical trial"},{"ns":0,"exists":"","*":"Copyright status of work by the U.S. government"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Direct costs"},{"ns":0,"exists":"","*":"Drug Enforcement Administration"},{"ns":0,"exists":"","*":"Drug development"},{"ns":0,"exists":"","*":"Eau Claire Leader-Telegram"},{"ns":0,"exists":"","*":"European Medicines Agency"},{"ns":0,"exists":"","*":"George H.W. Bush"},{"ns":0,"exists":"","*":"Glaucoma"},{"ns":0,"exists":"","*":"Google News"},{"ns":0,"exists":"","*":"Indirect costs"},{"ns":0,"exists":"","*":"International Standard Book Number"},{"ns":0,"exists":"","*":"International Standard Serial Number"},{"ns":0,"exists":"","*":"Investigational New Drug"},{"ns":0,"exists":"","*":"Investigational device exemption"},{"ns":0,"exists":"","*":"Investigational new drug"},{"ns":0,"exists":"","*":"Medical cannabis"},{"ns":0,"exists":"","*":"Medical necessity"},{"ns":0,"exists":"","*":"Medicines and Healthcare products Regulatory Agency"},{"ns":0,"exists":"","*":"National Health Service"},{"ns":0,"exists":"","*":"National Institute on Drug Abuse"},{"ns":0,"exists":"","*":"Orphan drug"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Right-to-try laws"},{"ns":0,"exists":"","*":"Robert C. Randall"},{"ns":0,"exists":"","*":"Simon & Schuster"},{"ns":0,"exists":"","*":"Supreme Court of the United States"},{"ns":0,"exists":"","*":"U.S. Court of Appeals for the District of Columbia Circuit"},{"ns":0,"exists":"","*":"United States Department of Justice"},{"ns":0,"exists":"","*":"University of Mississippi"},{"ns":0,"exists":"","*":"Washington Legal Foundation"},{"ns":0,"*":"Neurology Today"},{"ns":12,"exists":"","*":"Help:CS1 errors"},{"ns":14,"exists":"","*":"Category:CS1 maint: Uses authors parameter"}],"templates":[{"ns":10,"exists":"","*":"Template:HHS content"},{"ns":10,"exists":"","*":"Template:Include-USGov"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Citation"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:ISBN"},{"ns":10,"exists":"","*":"Template:Catalog lookup link"},{"ns":10,"exists":"","*":"Template:Trim"},{"ns":10,"exists":"","*":"Template:Yesno-no"},{"ns":10,"exists":"","*":"Template:Yesno"},{"ns":10,"exists":"","*":"Template:Error-small"},{"ns":10,"exists":"","*":"Template:Tl"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Cite news"},{"ns":10,"exists":"","*":"Template:Open access"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check isxn"},{"ns":828,"exists":"","*":"Module:Error"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":["Lock-green.svg","Open_Access_logo_PLoS_transparent.svg","U.S._Government_Medical_Marijuana_crop._University_of_Mississippi._Oxford.jpg","PD-icon.svg"],"externallinks":["//www.ncbi.nlm.nih.gov/pmc/articles/PMC4763516","//doi.org/10.4103/2229-3485.173779","//www.ncbi.nlm.nih.gov/pubmed/26955570","//doi.org/10.5582/irdr.2016.01054","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5116859","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4546220","//doi.org/10.1186/s13023-015-0306-x","//www.ncbi.nlm.nih.gov/pubmed/26292942","http://www.cancer.gov/cancertopics/factsheet/Therapy/investigational-drug-access","https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/default.htm","//doi.org/10.1056/NEJMhle1409465","//www.ncbi.nlm.nih.gov/pubmed/25587952","https://dx.doi.org/10.1056/NEJMhle1409465","//www.worldcat.org/issn/0028-4793","http://www.cancernetwork.com/oncology-journal/medical-ethicist-arthur-caplan-explains-why-he-opposes-right-try-laws","//doi.org/10.1016/j.jep.2006.02.001","//www.ncbi.nlm.nih.gov/pubmed/16540272","http://www.mapinc.org/drugnews/v97/n318/a03.html","https://books.google.com/books?id=n-SG3oWUjhMC&pg=PA234&lpg=PA234&dq=jacki+rickert&source=bl&ots=G49pTLqJnI&sig=9kzur-bBPe7kFWCK0ocPAQx0TmI&hl=en&sa=X&ved=0ahUKEwiSutbg453SAhVB5IMKHT1kDMY4HhDoAQgcMAE#v=onepage&q=jacki%20rickert&f=false","http://www.cbsnews.com/news/4-americans-get-medical-pot-from-the-feds/","//doi.org/10.1300/J175v01n03_03","//doi.org/10.1097/01.nt.0000337676.20893.50","http://www.ncahf.org/digest07/07-30.html","https://web.archive.org/web/20120305014138/http://afp.google.com/article/ALeqM5jgwM6ty2aFly_TqIoojwZCheBCsw","http://afp.google.com/article/ALeqM5jgwM6ty2aFly_TqIoojwZCheBCsw","https://www.cnn.com/2014/03/10/health/cohen-josh/index.html","https://www.kidsvcancer.org/saved-josh-the-gears-of-a-successful-patient-advocacy-campaign-case-study-by-elena-gerasimov/","https://www.cnn.com/2014/03/11/health/josh-hardy-drug-study/index.html","http://cancerres.aacrjournals.org/content/76/14_Supplement/LB-146","//doi.org/10.1158/1538-7445.AM2016-LB-146","//www.worldcat.org/issn/0008-5472","https://blogs.fda.gov/fdavoice/index.php/2017/10/expanded-access-fda-describes-efforts-to-ease-application-process/","https://www.medscape.com/viewarticle/864310","https://www.fda.gov/newsevents/publichealthfocus/expandedaccesscompassionateuse/ucm443572.htm"],"sections":[{"toclevel":1,"level":"2","line":"Programs","number":"1","index":"1","fromtitle":"Expanded_access","byteoffset":1837,"anchor":"Programs"},{"toclevel":2,"level":"3","line":"US","number":"1.1","index":"2","fromtitle":"Expanded_access","byteoffset":3361,"anchor":"US"},{"toclevel":3,"level":"4","line":"State law","number":"1.1.1","index":"3","fromtitle":"Expanded_access","byteoffset":7179,"anchor":"State_law"},{"toclevel":2,"level":"3","line":"Europe","number":"1.2","index":"4","fromtitle":"Expanded_access","byteoffset":8791,"anchor":"Europe"},{"toclevel":1,"level":"2","line":"History","number":"2","index":"5","fromtitle":"Expanded_access","byteoffset":9950,"anchor":"History"},{"toclevel":1,"level":"2","line":"See also","number":"3","index":"6","fromtitle":"Expanded_access","byteoffset":18780,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"4","index":"7","fromtitle":"Expanded_access","byteoffset":18812,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Expanded access","iwlinks":[],"properties":[{"name":"defaultsort","*":"Expanded Access"},{"name":"wikibase_item","*":"Q407954"}]}}